The Life Sciences Report
For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.
Notable Quotes
"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >
"ACRX has a revolutionary painkiller, Zalviso; the stock is a very good buy, with lots of upside." (2/20/14) AcelRx Pharmaceuticals Inc. - The Life Sciences Report Interview with Chen Lin More >
The Approval Process in Action
Source: The Life Sciences Report and Visual Capitalist (5/1/13)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
More Experts
"There is exciting potential for CYTX's therapy." (2/6/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Steve Brozak More >
"We believe ATHX is still undervalued." (2/6/14) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
"NBS' initial trial data has been positive beyond expectations." (2/6/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
"CPRX's Firdapse has both orphan drug status and breakthrough designation." (1/30/14) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Echo He More >
"BLFS has its own proprietary biopreservation media, and it has been doing very well." (12/19/13) BioLife Solutions Inc. - The Life Sciences Report Interview with Brian Marckx More >